tranScrip appoints Gareth Dyson as new Chief Financial Officer

London, U.K. 6th February 2024: tranScrip, the leading contract drug development organisation, announces that Gareth Dyson has been named Chief Financial Officer (“CFO”) with immediate effect. Gareth has a wealth of finance and leadership experience in Private Equity backed businesses and has a track record of driving significant growth and transformation in fast paced B2B environments. His experience spans financial management, mergers and acquisitions, systems implementation, and leading large teams.

Prior to joining tranScrip, Gareth was Chief Financial Officer at Redstor, a data management and protection vendor, where he completed one acquisitions and two successful private equity transactions.

Gareth’s expertise and experience will help tranScrip continue to develop and grow as a trusted partner for the pharmaceutical and biotech industry and help make a real difference to the lives of patients.

Mark Corbett, tranScrip’s CEO, said:

“We are delighted to welcome Gareth Dyson as tranScrip’s new Chief Financial Officer. Gareth’s proven track record in driving growth and transformation in Private Equity backed businesses makes him an excellent addition to our leadership team. His expertise in financial management, mergers and acquisitions, and leading large teams aligns seamlessly with tranScrip’s vision for continued success. We look forward to leveraging Gareth’s skills to further strengthen our position as a leading contract drug development organization, providing strategic leadership and operational execution of development and commercialisation programmes  for the pharmaceutical and biotech industry.”

Gareth Dyson, tranScrip’s CFO, said:

“I am honoured to join tranScrip as the Chief Financial Officer and contribute to the company’s mission of making a real impact in the pharmaceutical and biotech sector. tranScrip has a solid reputation as a trusted partner, and I am excited to bring my financial and leadership experience to drive innovation and growth. I believe that my background in Private Equity, coupled with tranScrip’s commitment to excellence, will enable us to navigate the evolving landscape of drug development successfully. I look forward to working closely with the team to build on tranScrip’s achievements and deliver value to both our clients and patients.”